INCY Incyte's Phase 3 Retifanlimab Anal Cancer Trial Listed as Completed The POD1UM-303/InterAACT 2 study of retifanlimab added to carboplatin-paclitaxel in advanced anal cancer now carries COMPLETED status on ClinicalTrials.gov.
